EWTX
Edgewise Therapeutics, Inc.$31.15+0.55 (+1.80%)Prev Close$30.64·MCap$3.39B·P/E—·Vol3.18M·Yield—
▲
Buys (12M)
1
$199.4K
▼
Sells (12M)
18
$9.60M
◆
Net Activity
Net Seller
$9.40M
●
Active Insiders
8
last 12 mo
Over the past 12 months, insider activity at Edgewise Therapeutics, Inc. (EWTX) has been dominated by selling, with 1 insider purchase totaling $199.4K and 18 insider sales totaling $9.60M. The most recent insider transaction was by Donovan Joanne M. (officer: CMO), who sold $926.1K worth of shares on Apr 2, 2026. Edgewise Therapeutics, Inc. operates in the Healthcare sector, within the Biotechnology industry, with a market cap of $3.39B.
EWTX Insider Trading Activity
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Apr 2, 2026 | Donovan Joanne M. | officer: CMO | Sell | 28,662 | $32.31 | $926.1K | 9,597-75% |
| Mar 31, 2026 | Donovan Joanne M. | officer: CMO | Sell | 21,338 | $32.12 | $685.3K | 9,597-69% |
| Mar 30, 2026 | Donovan Joanne M. | officer: CMO | Sell | 16,358 | $30.98 | $506.7K | 16,332-50% |
| Jan 21, 2026 | Edris Badreddin | Director | Sell | 115,471 | $29.44 | $3.40M | 0 |
| Nov 12, 2025 | Russell Alan J | Chief Scientific Officer | Sell | 100,000 | $21.12 | $2.11M | 0 |
| Nov 11, 2025 | Fox Jonathan C | Director | Buy | 10,700 | $18.64 | $199.4K | 0 |
| Aug 26, 2025 | Russell Alan J | Chief Scientific Officer | Sell | 100,000 | $14.60 | $1.46M | 0 |
| Aug 12, 2025 | Carruthers R Michael | Chief Financial Officer | Sell | 1,428 | $13.39 | $19.1K | 0 |
| Aug 12, 2025 | Derakhshan Behrad | Chief Business Officer | Sell | 2,491 | $13.39 | $33.4K | 0 |
| Aug 12, 2025 | Donovan Joanne M. | CMO | Sell | 2,862 | $13.39 | $38.3K | 0 |
| Aug 12, 2025 | KOCH KEVIN | President and CEO | Sell | 7,972 | $13.39 | $106.8K | 0 |
| Aug 12, 2025 | MOORE JOHN R | General Counsel | Sell | 2,098 | $13.39 | $28.1K | 0 |
| Aug 12, 2025 | Russell Alan J | Chief Scientific Officer | Sell | 1,907 | $13.39 | $25.5K | 0 |
| May 1, 2025 | Carruthers R Michael | Chief Financial Officer | Sell | 1,314 | $16.45 | $21.6K | 0 |
| May 1, 2025 | Derakhshan Behrad | Chief Business Officer | Sell | 1,691 | $16.45 | $27.8K | 0 |
| May 1, 2025 | Donovan Joanne M. | CMO | Sell | 5,187 | $16.45 | $85.3K | 0 |
| May 1, 2025 | KOCH KEVIN | President and CEO | Sell | 4,276 | $16.45 | $70.4K | 0 |
| May 1, 2025 | MOORE JOHN R | General Counsel | Sell | 1,930 | $16.45 | $31.8K | 0 |
| May 1, 2025 | Russell Alan J | Chief Scientific Officer | Sell | 1,551 | $16.45 | $25.5K | 0 |
| Apr 3, 2025 | Thompson Peter A. | Director | Buy | 496,771 | $20.13 | $10.00M | 0 |
| Mar 7, 2025 | KOCH KEVIN | President and CEO | Sell | 100 | $30.00 | $3.0K | 0 |
| Mar 7, 2025 | Russell Alan J | Chief Scientific Officer | Sell | 200 | $30.02 | $6.0K | 0 |
| Feb 7, 2025 | Derakhshan Behrad | Chief Business Officer | Sell | 10,000 | $30.03 | $300.3K | 16,837-37% |
| Feb 7, 2025 | KOCH KEVIN | President and CEO | Sell | 9,536 | $30.13 | $287.3K | 14,478-40% |
| Feb 7, 2025 | Russell Alan J | Chief Scientific Officer | Sell | 9,215 | $30.04 | $276.8K | 14,863-38% |
| Jan 30, 2025 | Donovan Joanne M. | CMO | Sell | 25,000 | $27.63 | $690.7K | 16,358-60% |
| Dec 31, 2024 | Russell Alan J | Chief Scientific Officer | Sell | 100,000 | $27.37 | $2.74M | 14,863-87% |
| Dec 27, 2024 | Semigran Marc | Chief Development Officer | Sell | 29,709 | $29.69 | $881.9K | 8,445-78% |
| Sep 24, 2024 | Carruthers R Michael | Chief Financial Officer | Sell | 125,092 | $28.57 | $3.57M | 35,928-78% |
| Sep 24, 2024 | Derakhshan Behrad | Chief Business Officer | Sell | 42,068 | $29.03 | $1.22M | 15,121-74% |
| Sep 24, 2024 | Donovan Joanne M. | CMO | Sell | 7,162 | $28.29 | $202.6K | 14,538-33% |
| Sep 24, 2024 | MOORE JOHN R | General Counsel | Sell | 70,922 | $28.15 | $2.00M | 3,252-96% |
| Sep 24, 2024 | Russell Alan J | Chief Scientific Officer | Sell | 75,000 | $28.27 | $2.12M | 13,534-85% |
| May 3, 2024 | Carruthers R Michael | Chief Financial Officer | Sell | 2,157 | $18.91 | $40.8K | 35,230 |
| May 3, 2024 | Derakhshan Behrad | Chief Business Officer | Sell | 1,718 | $18.91 | $32.5K | 13,422 |
| May 3, 2024 | Donovan Joanne M. | CMO | Sell | 3,682 | $18.91 | $69.6K | 19,897 |
| May 3, 2024 | KOCH KEVIN | President and CEO | Sell | 3,152 | $18.91 | $59.6K | 14,478 |
| May 3, 2024 | MOORE JOHN R | General Counsel | Sell | 1,956 | $18.91 | $37.0K | 3,252-38% |
| May 3, 2024 | Russell Alan J | Chief Scientific Officer | Sell | 1,576 | $18.91 | $29.8K | 7,238 |
| Feb 9, 2024 | Derakhshan Behrad | Chief Business Officer | Sell | 10,000 | $20.03 | $200.3K | 7,020-59% |
| Feb 9, 2024 | MOORE JOHN R | General Counsel | Sell | 29,835 | $20.00 | $596.8K | 0Exit |
| Jan 25, 2024 | Carruthers R Michael | Chief Financial Officer | Sell | 90,000 | $15.78 | $1.42M | 29,024-76% |
| Jan 25, 2024 | Thompson Peter A. | Director | Buy | 454,545 | $11.00 | $5.00M | 14,436,497 |
| Dec 28, 2023 | Fox Jonathan C | Buy | 10,857 | $9.30 | $101.0K | 10,857 | |
| Dec 28, 2023 | MOORE JOHN R | General Counsel | Sell | 8,497 | $10.50 | $89.2K | 0Exit |
| Dec 28, 2023 | Russell Alan J | Chief Scientific Officer | Sell | 172,585 | $9.33 | $1.61M | 3,606-98% |
| May 3, 2023 | Carruthers R Michael | Chief Financial Officer | Sell | 1,336 | $8.90 | $11.9K | 16,126 |
| May 3, 2023 | Derakhshan Behrad | Chief Business Officer | Sell | 1,747 | $8.90 | $15.6K | 7,020 |
| May 3, 2023 | Donovan Joanne M. | CMO | Sell | 3,254 | $8.90 | $29.0K | 9,960 |
| May 3, 2023 | KOCH KEVIN | President and CEO | Sell | 3,203 | $8.90 | $28.5K | 7,213-31% |
Showing 1–50 of 78
1 / 2
EWTX Insider Buying Activity
The following table shows recent insider purchases of Edgewise Therapeutics, Inc. (EWTX) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Nov 11, 2025 | Fox Jonathan C | Director | Buy | 10,700 | $18.64 | $199.4K | 0 |
| Apr 3, 2025 | Thompson Peter A. | Director | Buy | 496,771 | $20.13 | $10.00M | 0 |
| Jan 25, 2024 | Thompson Peter A. | Director | Buy | 454,545 | $11.00 | $5.00M | 14,436,497 |
| Dec 28, 2023 | Fox Jonathan C | Buy | 10,857 | $9.30 | $101.0K | 10,857 |
EWTX Insider Selling Activity
The following table shows recent insider sales of Edgewise Therapeutics, Inc. (EWTX) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Apr 2, 2026 | Donovan Joanne M. | officer: CMO | Sell | 28,662 | $32.31 | $926.1K | 9,597-75% |
| Mar 31, 2026 | Donovan Joanne M. | officer: CMO | Sell | 21,338 | $32.12 | $685.3K | 9,597-69% |
| Mar 30, 2026 | Donovan Joanne M. | officer: CMO | Sell | 16,358 | $30.98 | $506.7K | 16,332-50% |
| Jan 21, 2026 | Edris Badreddin | Director | Sell | 115,471 | $29.44 | $3.40M | 0 |
| Nov 12, 2025 | Russell Alan J | Chief Scientific Officer | Sell | 100,000 | $21.12 | $2.11M | 0 |
| Aug 26, 2025 | Russell Alan J | Chief Scientific Officer | Sell | 100,000 | $14.60 | $1.46M | 0 |
| Aug 12, 2025 | Carruthers R Michael | Chief Financial Officer | Sell | 1,428 | $13.39 | $19.1K | 0 |
| Aug 12, 2025 | Derakhshan Behrad | Chief Business Officer | Sell | 2,491 | $13.39 | $33.4K | 0 |
| Aug 12, 2025 | Donovan Joanne M. | CMO | Sell | 2,862 | $13.39 | $38.3K | 0 |
| Aug 12, 2025 | KOCH KEVIN | President and CEO | Sell | 7,972 | $13.39 | $106.8K | 0 |
| Aug 12, 2025 | MOORE JOHN R | General Counsel | Sell | 2,098 | $13.39 | $28.1K | 0 |
| Aug 12, 2025 | Russell Alan J | Chief Scientific Officer | Sell | 1,907 | $13.39 | $25.5K | 0 |
| May 1, 2025 | Carruthers R Michael | Chief Financial Officer | Sell | 1,314 | $16.45 | $21.6K | 0 |
| May 1, 2025 | Derakhshan Behrad | Chief Business Officer | Sell | 1,691 | $16.45 | $27.8K | 0 |
| May 1, 2025 | Donovan Joanne M. | CMO | Sell | 5,187 | $16.45 | $85.3K | 0 |
| May 1, 2025 | KOCH KEVIN | President and CEO | Sell | 4,276 | $16.45 | $70.4K | 0 |
| May 1, 2025 | MOORE JOHN R | General Counsel | Sell | 1,930 | $16.45 | $31.8K | 0 |
| May 1, 2025 | Russell Alan J | Chief Scientific Officer | Sell | 1,551 | $16.45 | $25.5K | 0 |
| Mar 7, 2025 | KOCH KEVIN | President and CEO | Sell | 100 | $30.00 | $3.0K | 0 |
| Mar 7, 2025 | Russell Alan J | Chief Scientific Officer | Sell | 200 | $30.02 | $6.0K | 0 |
| Feb 7, 2025 | Derakhshan Behrad | Chief Business Officer | Sell | 10,000 | $30.03 | $300.3K | 16,837-37% |
| Feb 7, 2025 | KOCH KEVIN | President and CEO | Sell | 9,536 | $30.13 | $287.3K | 14,478-40% |
| Feb 7, 2025 | Russell Alan J | Chief Scientific Officer | Sell | 9,215 | $30.04 | $276.8K | 14,863-38% |
| Jan 30, 2025 | Donovan Joanne M. | CMO | Sell | 25,000 | $27.63 | $690.7K | 16,358-60% |
| Dec 31, 2024 | Russell Alan J | Chief Scientific Officer | Sell | 100,000 | $27.37 | $2.74M | 14,863-87% |
| Dec 27, 2024 | Semigran Marc | Chief Development Officer | Sell | 29,709 | $29.69 | $881.9K | 8,445-78% |
| Sep 24, 2024 | Carruthers R Michael | Chief Financial Officer | Sell | 125,092 | $28.57 | $3.57M | 35,928-78% |
| Sep 24, 2024 | Derakhshan Behrad | Chief Business Officer | Sell | 42,068 | $29.03 | $1.22M | 15,121-74% |
| Sep 24, 2024 | Donovan Joanne M. | CMO | Sell | 7,162 | $28.29 | $202.6K | 14,538-33% |
| Sep 24, 2024 | MOORE JOHN R | General Counsel | Sell | 70,922 | $28.15 | $2.00M | 3,252-96% |
| Sep 24, 2024 | Russell Alan J | Chief Scientific Officer | Sell | 75,000 | $28.27 | $2.12M | 13,534-85% |
| May 3, 2024 | Carruthers R Michael | Chief Financial Officer | Sell | 2,157 | $18.91 | $40.8K | 35,230 |
| May 3, 2024 | Derakhshan Behrad | Chief Business Officer | Sell | 1,718 | $18.91 | $32.5K | 13,422 |
| May 3, 2024 | Donovan Joanne M. | CMO | Sell | 3,682 | $18.91 | $69.6K | 19,897 |
| May 3, 2024 | KOCH KEVIN | President and CEO | Sell | 3,152 | $18.91 | $59.6K | 14,478 |
| May 3, 2024 | MOORE JOHN R | General Counsel | Sell | 1,956 | $18.91 | $37.0K | 3,252-38% |
| May 3, 2024 | Russell Alan J | Chief Scientific Officer | Sell | 1,576 | $18.91 | $29.8K | 7,238 |
| Feb 9, 2024 | Derakhshan Behrad | Chief Business Officer | Sell | 10,000 | $20.03 | $200.3K | 7,020-59% |
| Feb 9, 2024 | MOORE JOHN R | General Counsel | Sell | 29,835 | $20.00 | $596.8K | 0Exit |
| Jan 25, 2024 | Carruthers R Michael | Chief Financial Officer | Sell | 90,000 | $15.78 | $1.42M | 29,024-76% |
| Dec 28, 2023 | MOORE JOHN R | General Counsel | Sell | 8,497 | $10.50 | $89.2K | 0Exit |
| Dec 28, 2023 | Russell Alan J | Chief Scientific Officer | Sell | 172,585 | $9.33 | $1.61M | 3,606-98% |
| May 3, 2023 | Carruthers R Michael | Chief Financial Officer | Sell | 1,336 | $8.90 | $11.9K | 16,126 |
| May 3, 2023 | Derakhshan Behrad | Chief Business Officer | Sell | 1,747 | $8.90 | $15.6K | 7,020 |
| May 3, 2023 | Donovan Joanne M. | CMO | Sell | 3,254 | $8.90 | $29.0K | 9,960 |
| May 3, 2023 | KOCH KEVIN | President and CEO | Sell | 3,203 | $8.90 | $28.5K | 7,213-31% |
EWTX Insiders
Similar Stocks to EWTX
VRTX
Vertex Pharmaceuticals Incorporated
$429.47+0.81%
$111.71B
REGN
Regeneron Pharmaceuticals, Inc.
$734.06-1.39%
$77.87B
ALNY
Alnylam Pharmaceuticals, Inc.
$303.44-1.64%
$41.24B
INSM
Insmed Incorporated
$135.11-0.64%
$30.79B
RVMD
Revolution Medicines, Inc.
$144.62+9.92%
$29.51B
UTHR
United Therapeutics Corporation
$566.69+0.03%
$25.13B
MRNA
Moderna, Inc.
$47.16-3.17%
$21.42B
RPRX
Royalty Pharma plc
$49.40-0.50%
$21.20B